Bristol Myers Squibb Appoints GM of Saudi Arabia and Gulf Countries

Bristol Myers Squibb (BMS), a global biopharmaceutical company, has appointed Mayada Al-Ahmad to the position of General Manager of Saudi Arabia and Gulf Countries.

In this role, Al-Ahmad will lead the affiliate spanning Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan, with responsibility for advancing BMS’s mission to deliver transformative medicines to patients across the region.

“As she assumes this new leadership role, Mayada’s deep understanding of the Saudi and Gulf markets along with her strong regional network, position her well to lead this important affiliate into its next phase of growth. Her leadership will be instrumental in advancing our mission across the region, aligning seamlessly with national & regional health transformation priorities.” said Michelle Calope, Senior Vice President | Head of Intercontinental Markets, Bristol Myers Squibb.

Experience

Al-Ahmad brings over 24 years of progressive leadership experience in the pharmaceutical industry, spanning commercial, strategic, and country management functions across diverse geographies, including the Middle East, Africa, Türkiye, Russia, and Intercontinental markets. She has broad therapeutic expertise in Oncology, Hematology, Cardiovascular, Neuroscience, and Diabetes; and has demonstrated an ability to drive performance and cultivate strong, high-performing, patient-centric teams within varied and challenging market environments.

Commenting on her new appointment, she remarked: “I am honored and enthusiastic to step into this pivotal role, leading Bristol Myers Squibb’s efforts across Saudi Arabia and the Gulf Countries. It is a privilege to contribute to our vital mission of delivering innovative medicines and making a meaningful difference in patients’ lives throughout this dynamic region. I look forward to working closely with our talented team and valued partners to further our commitment to health and scientific advancement.”

More BMS News

Bristol Myers Squibb recently signed a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions.